GlobalData on MSN
FDA oncology roundup: AbbVie’s rare cancer approval, AstraZeneca in breast cancer limbo
AbbVie’s ADC has secured FDA clearance for an ultra-rare blood cancer while the agency has delayed its decision on ...
The FDA has delayed a decision on the approval of AstraZeneca’s camizestrant, deferring its ruling to review analyses filed ...
AstraZeneca has fired another volley in its bladder cancer competition with Merck’s Keytruda, with the FDA on Thursday ...
The review extension comes weeks after an advisory panel found the evidence supporting the drug, camizestrant, inconclusive ...
US FDA approves AstraZeneca’s Imfinzi for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer: Cambridge, UK Saturday, May 30, 2026, 13:00 Hrs [IST] AstraZene ...
May 27 (Reuters) - AstraZeneca said on Wednesday the U.S. Food and Drug Administration has extended the decision deadline for ...
Three new cancer drugs could help AstraZenecaAZN make a dent in its lofty ambition to become an $80 billion company by 2030, an executive told Investor's Business Daily. On Sunday and Monday, ...
This extension follows an April vote by a majority of the FDA's advisory panel against the drug when used in combination with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results